Cargando…

Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy

Immune-related adverse events (irAEs) can impair the effectiveness and safety of immune checkpoint inhibitors (ICIs) and restrict the clinical applications of ICIs in oncology. The predictive biomarkers of irAE are urgently required for early diagnosis and subsequent management. The exact mechanism...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Xiujing, Yu, Jing, Shi, Hubing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652050/ https://www.ncbi.nlm.nih.gov/pubmed/34899357 http://dx.doi.org/10.3389/fphar.2021.797852

Ejemplares similares

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
por: Yang, Jiqiao, et al.
Publicado: (2019)

Editorial: Targeting the PD-1/PD-L1 cancer immune evasion axis: Challenges and emerging strategies, Volume II
por: He, Xiujing, et al.
Publicado: (2022)

Immune-related adverse events of biological immunotherapies used in COVID-19
por: Baracaldo-Santamaría, Daniela, et al.
Publicado: (2022)

Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review
por: Gao, Ling, et al.
Publicado: (2019)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Bai, Xiaoyin, et al.
Publicado: (2021)

Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
por: Zhang, Yue, et al.
Publicado: (2022)

Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study
por: Liu, Hao, et al.
Publicado: (2023)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

Integrating machine learning to construct aberrant alternative splicing event related classifiers to predict prognosis and immunotherapy response in patients with hepatocellular carcinoma
por: Liu, Wangrui, et al.
Publicado: (2022)

Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer
por: Sun, Liting, et al.
Publicado: (2023)

A Pan-Cancer Analysis of Alternative Splicing Events Reveals Novel Tumor-Associated Splice Variants of Matriptase
por: Dargahi, Daryanaz, et al.
Publicado: (2014)

Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2022)

Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
por: Zheng, Dan, et al.
Publicado: (2022)

Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer
por: Wu, Yanmeizhi, et al.
Publicado: (2022)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Ma, Zhuo, et al.
Publicado: (2021)

Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study
por: Les, Iñigo, et al.
Publicado: (2022)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
por: Jing, Ying, et al.
Publicado: (2020)

Survival-Associated Alternative Splicing Events in Pan-Renal Cell Carcinoma
por: Jia, Keren, et al.
Publicado: (2019)

Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database
por: Kato, Koki, et al.
Publicado: (2022)

Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis
por: Lin, Li, et al.
Publicado: (2023)

Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Da, Lijun, et al.
Publicado: (2020)

Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials
por: Zhang, Weidong, et al.
Publicado: (2021)

Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
por: Choi, Juwhan, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
por: Ruggiero, Rosanna, et al.
Publicado: (2020)

Microbiota and their metabolites potentiate cancer immunotherapy: Therapeutic target or resource for small molecule drug discovery?
por: Du, Peixin, et al.
Publicado: (2022)

A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy
por: Yang, Jing, et al.
Publicado: (2022)

Current landscape and tailored management of immune-related adverse events
por: Liu, Wenhui, et al.
Publicado: (2023)

Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events
por: Bai, Rilan, et al.
Publicado: (2021)

Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials
por: Ge, Yang, et al.
Publicado: (2021)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023)

Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023)

In-situ formed thermosensitive hydrogel amplifies statin-mediated immune checkpoint blockade for coordinated tumor chemo-immunotherapy
por: Liu, Zefan, et al.
Publicado: (2023)

Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer
por: van Holstein, Yara, et al.
Publicado: (2019)

Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival
por: Yamada, Kentaro, et al.
Publicado: (2021)

Editorial: Immune-Related Adverse Events for Patients With Lung Cancer
por: Yang, Ruoning, et al.
Publicado: (2022)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
por: Brahmer, Julie R, et al.
Publicado: (2021)

Pan-immune-inflammation and its dynamics: predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy
por: Chen, Yiqun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jjagbs99at4qkor0a7mpk83tqh